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ABSTRACT
Background: Data on the natural change in renal function in patients with chronic heart failure (HF) are
limited.
Methods and Results: Estimated glomerular filtration rate (eGFR) was assessed over 36 months in 6934
patients included in the GISSI-HF study. Associations from baseline, changes in renal function, and oc-
currence of cardiovascular death or HF hospitalization were assessed. Mean age was 67 years, mainly men
(78%), and mean eGFR was 68 mL • min−1 • 1.73 m−2. Change in eGFR in the 1st year was
−1.5 ± 16 mL • min−1 • 1.73 m−2, and over 36 months it was −3.7 ± 18 mL • min−1 • 1.73 m−2. Over the latter
period, only 25% deteriorated ≥1 Kidney Disease Outcomes Quality Initiatives (KDOQI) class of chronic
kidney disease (CKD). Fifteen percent of patients had >15 mL • min−1 • 1.73 m−2 decrease in eGFR in the
1st 12 months. Lower eGFR was associated with outcome: hazard ratio (HR) 1.10, 95% confidence inter-
val (CI) 1.08–1.10 (P < .001) per 10 mL • min−1 • 1.73 m−2 decrease, as well as every 10 mL • min−1 • 1.73 m−2
decrease over the 1st year (HR 1.10, 95% CI 1.04–1.17; P < .001). A deterioration in eGFR
>15 mL • min−1 • 1.73 m−2 in the 1st year showed the highest risk of events (HR 1.22, 95% CI 1.10–1.36;
P < .001).
Conclusions: Mean decrease in renal function over time in patients with chronic HF was modest. Only
25% deteriorated ≥1 KDOQI class of CKD after 3 years. Any decrease in eGFR over time was associated
with strongly increased event rates. (J Cardiac Fail 2017;23:2–9)
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Renal function as estimated by glomerular filtration rate
(eGFR) generally declines ~0.5-1.0 mL • min−1 • 1.73 m−2 per
year.1 Any decline in renal function, or the presence of a reduced
GFR at any point in time, has been associated with worse out-
comes in multiple populations.2 This is also the case for renal
impairment in chronic heart failure (HF), which is strongly as-
sociated with increased event rates. In a recent meta-analysis
of >1 million subjects, the presence of chronic kidney disease
(CKD; usually defined as eGFR <60 mL • min−1 • 1.73 m−2) was
associated with a >2-fold increase in all-cause mortality rates.3
Additionally, recent research has shown that a deterioration of
renal function, or more importantly, an increase in serum cre-
atinine, is associated with a further increase in mortality.3,4
However, the circumstances during which this “worsening renal
function” (WRF) develops seem far more important than the
occurrence of WRF itself.5 Although multiple reports focused
on these changes, most evaluated WRF during a short follow-
up time, only limited reports evaluated the progression of CKD
or deterioration of renal function (ie, GFR) over a longer period
of time. In fact, limited data are available on the “normal”
decline in renal function in patients with HF. In the present anal-
ysis from the GISSI-HF (Effects of n-3 Polyunsaturated Fatty
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Acids [PUFA] and Rosuvastatin on Mortality-Morbidity of Pa-
tients With Symptomatic Congestive Heart Failure; Gruppo
Italiano per lo Studio della Sopravvivenza nell’Insufficienza
Cardiaca study, we investigated the “natural course” of change
in GFR, the progression of stages of CKD, and the associ-
ated prognosis in patients with chronic HF.
Methods
GISSI-HF was a randomized, double-blinded, placebo-
controlled, multicenter study that enrolled 6975 patients with
clinical evidence of HF (NewYork Heart Association [NYHA]
functional class II–IV). Patients were randomly assigned in
a nested design to 1 g daily n-3 PUFA or placebo, and for
those who were eligible, to 10 mg daily rosuvastatin or placebo.
The design and results of the main trial have been published.6–8
Patients with a baseline serum creatinine >2.5 mg/dL
(222 μmol/L) were excluded from the rosuvastatin substudy.
GFR and CKD
Estimated GFR was calculated with the use of the simpli-
fied Modification of Diet in Renal Disease (sMDRD) formula
at baseline and 1, 3, 6, 12, 24, and 36 months. Serum creati-
nine was available in 6934, 6159, 6061, 5715, 4956, 4104
patients at randomization, 3 months, 6 months, 1 year, 2 years,
and 3 years, respectively. This formula was selected because
it was used in earlier analyses from GISSI-HF. CKD was clas-
sified with the use of the Kidney Disease Outcomes Quality
Initiatives (KDOQI) classification (all in mL • min−1 • 1.73 m−2):
eGFR ≥90, class I; eGFR <90 and ≥60, class II; eGFR <60
and ≥30, class III; eGFR <30 and ≥15, class IV; and finally
eGFR <15, class V. Early change in eGFR was determined as
the change in eGFR during the 1st year of follow-up and was
categorized in the following groups: >15, 15-10, 5–10, and
0–5 mL • min−1 • 1.73 m−2 decrease and >0 mL • min−1 • 1.73 m−2
increase in eGFR.
Clinical Outcome
The primary outcome was the 1st occurrence of either car-
diovascular (CV) death or HF hospitalization as adjudicated
in the original GISSI-HF study. Secondary outcome in-
cluded each individual component: CV death or HF
Hospitalization.
Statistical Analysis
Categoric variables are presented as percentages, while con-
tinuous variables are presented as mean and SD or as median
and interquartile range (IQR).
Categoric variables were compared by means of the chi-
square test and continuous variables by means of analysis of
variance or Kruskal-Wallis test. Change in renal function was
assessed with the use of repeated-measures mixed-effects mod-
eling, setting all baseline variables as fixed effects, patient
identification as random effects, and time as the within-
subject variable. This method uses all available data, including
baseline data and data of deceased subjects, that are avail-
able until death. Interaction analysis was used to assess possible
effect modification of baseline characteristics on the slope of
eGFR over time. All variables of relevant clinical interest were
included in the multivariable Cox model to identify the effect
of eGFR on the primary end point and included age, sex, body
mass index, NYHA functional class, etiology of HF, left ven-
tricular ejection fraction (LVEF), heart rate, systolic and
diastolic blood pressures, serum potassium, triglycerides,
history of hypertension, atrial fibrillation, diabetes, chronic
obstructive pulmonary disease (COPD), and cerebrovascu-
lar disease, and the use of concomitant medication (diuretics,
angiotensin-converting enzyme inhibitors, angiotensin re-
ceptor blockers, beta-blockers, spironolactone, or statins).
Linearity of eGFR was tested by means of restricted cubic
spline transformation. For the association between early change
in eGFR and outcome, patients with events in the 1st year
were excluded from the analysis. A P value of <.05 was con-
sidered to be statistically significant. All tests were two-
sided. Analyses were performed with R9 and the packages Rms
(regression modeling strategies; Frank E. Harrell Jr [2014];
R package version 4.2-0; http://CRAN.R-project.org/
package=rms) and Reporttools (Kaspar Rufibach [2009];
Report tools: R Functions to Generate LaTeX Tables of De-
scriptive Statistics, Journal of Statistical Software, Code
Snippets, 31[1]; http://www.jstatsoft.org/v31/c01/).
Results
Baseline Characteristics and Baseline Renal
Function/CKD
A total of 6934 patients had data on baseline serum cre-
atinine available. The patients were mainly male (78%), with
an overall mean age of 67 years and a mean LVEF of 33%.
Baseline eGFR was 68 mL • min−1 • 1.73 m−2, which was
higher in men (70 mL • min−1 • 1.73 m−2) than in women
(62 mL • min−1 • 1.73 m−2; P < .001).
Change in Renal Function Over Time
The mean change in eGFR over time in the entire study pop-
ulation is depicted in Fig. 1. In the first 12 months, the mean
change in eGFR was −1.5 ± 16 mL • min−1 • 1.73 m−2, whereas
it was 3.7 ± 18 mL • min−1 • 1.73 m−2 over the entire study period
of 36 months. This translated into a median decline in eGFR
of 2.57 mL • min−1 • 1.73 m−2/year. A total of 842 patients
(14.8%) had a decrease of >15 mL • min−1 • 1.73 m−2 in the 1st
year. Prevalence of −15 to −5 mL • min−1 • 1.73 m−2 in the
1st year was 19.8%; −5 to +5 mL • min−1 • 1.73 m−2,
31.3%; +5 to +15 mL • min−1 • 1.73 m−2, 23.5%; and
>15 mL • min−1 • 1.73 m−2 increase in 1 year 10.5% . Table 1
presents the baseline characteristics when stratified for these
changes in eGFR.
Among subsets of patients, we found limited interactions
between the slope of eGFR over time and the presence or absence
of specific conditions. Specifically, we found no evidence of
interaction between time and the association with the slope of
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eGFR for diabetes, hypertension, atrial fibrillation, age, NYHA
functional class, and most therapies, including randomized
rosuvastatin or n-3 PUFA treatment. We did find significant in-
teractions for the presence or absence of COPD (steeper decline
in eGFR when COPD was present), loop diuretic use (earlier
and steeper decline of eGFR with loop diuretic use, overall
similar decline after 36 months), and evidence of impaired renal
function at baseline (Fig. 2). For the latter, we found that pa-
tients with relatively preserved renal function (higher eGFR or
lower creatinine) had steeper decline of eGFR over time com-
pared with those with already compromised renal function.
Progression of CKD
At baseline, the distribution of patients according to KDOQI
stages of CKD was class I, 14.9%; class II, 47.5%; class III,
34.3%; class IV, 3.1%; and class V, 0.2%. In the 1st 12 months,
overall 19% of patients deteriorated ≥1 stage of CKD and 14%
of patients improved ≥1 stage (67% remained stable). After
36 months of follow-up, the distribution of patients accord-
ing to KDOQI stages had changed to class I, 14.6%; class
II, 46.6%; class III, 36.0%; class IV, 3.9%; and class V, 0.4%.
Overall, 25% of patients had deteriorated ≥1 class and 14%
had improved ≥1 class.
Renal Function, Changes in Renal Function, and
Clinical Outcome
In this study, a total of 3756 patients reached the primary
end point of either CV death of HF hospitalization. Exclud-
ing the subjects who died, the censored times were in the range
0–70 months (median ~50 mo, IQR 41–55 mo). Lower base-
line eGFR was associated with increased event rates (hazard
Fig. 1. Change in estimated glomerular filtration rate (eGFR) in pa-
tients with creatinine/eGFR available at all time points.
Table 1. Baseline Characteristics According to Change in Estimated Glomerular Filtration Rate (eGFR; mL • min−1 • 1.73 m−2) Over the
First Year
>15 Decrease 5–15 Decrease −5 to +5 (Stable) 5–15 Increase >15 Increase P Value
n (%) 599 (14.8) 1124 (19.8) 1785 (31.3) 1338 (23.5) 842 (10.5)
Age, y 64 ± 11 67 ± 11 68 ± 10 68 ± 10 66 ± 11 <.001
Sex (male, %) 78 79 78 78 79 .97
BMI (kg/m2) 28 ± 5 27 ± 4 27 ± 4 27 ± 4 27 ± 5 .39
NYHA III–IV (%) 35 30 33 35 34 .09
Ischemic HF (%) 42 47 51 51 47 <.001
LVEF, % 33 ± 8 33 ± 8 33 ± 8 33 ± 9 33 ± 8 .76
HR, beats/min 73 ± 14 72 ± 13 72 ± 13 71 ± 13 73 ± 13 .04
SBP, mm Hg 126 ± 18 126 ± 18 128 ± 18 127 ± 18 126 ± 17 .01
DBP, mm Hg 77 ± 10 77 ± 10 77 ± 10 77 ± 10 77 ± 10 .98
Potassium, mmol/L 4.5 ± 0.5 4.5 ± 0.5 4.5 ± 0.5 4.4 ± 0.5 4.4 ± 0.5 <.001
Triglycerides, mg/dL 147 ± 84 154 ± 99 155 ± 107 145 ± 87 139 ± 90 <.001
Serum creatinine, mg/dL 1.2 ± 0.6 1.2 ± 0.4 1.3 ± 0.5 1.1 ± 0.4 0.9 ± 0.2 <.001
eGFR, mL • min−1 • 1.73 m−2 66 ± 21 64 ± 19 65 ± 21 70 ± 19 88 ± 28 <.001
KDOQI classification (%) <.001
eGFR ≥90 mL • min−1 • 1.73 m−2 11 8 11 14 41
eGFR 60 – 89 mL • min−1 • 1.73 m−2 49 51 45 56 46
eGFR 30 – 59 mL • min−1 • 1.73 m−2 36 38 40 29 13
eGFR <30 mL • min−1 • 1.73 m−2 4 3 4 1 0
Medical history (%)
Hypertension 52 54 55 56 55 .49
Diabetes 25 26 28 29 27 .33
Atrial fibrillation 17 18 18 20 19 .61
COPD 20 18 21 23 21 .02
Stroke or TIA 5 4 5 6 4 .16
Medication (%)
ACEi or ARB 93 94 93 95 95 .08
Beta-blockers 69 67 66 69 65 .28
Diuretics 87 89 88 89 89 .53
Spironolactone 41 38 37 42 40 .03
Statin 24 22 25 23 22 .15
ICD therapy (%) 7 8 7 6 6 .07
BMI, body mass index; NYHA, New York Heart Association functional class; HF, heart failure; LVEF, left ventricular ejection fraction; HR, heart rate,
SBP, systolic blood pressure; SBP, diastolic blood pressure; KDOQI, Kidney Disease Outcomes Quality Initiatives, COPD, chronic obstructive pulmonary
disease; TIA, transient ischemic attack; ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ICD, implantable cardioverter-defibrillator.
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ratio [HR] 1.10 per 10 mL • min−1 • 1.73 m−2, 95% confidence
interval [CI] 1.08–1.10; P < .001), but the trend appeared to
be nonlinear. Cox regression performed after restricted cubic
splines transformation of eGFR showed a significant non-
linear component (P < .01), and the plot of the log-relative
hazard vs eGFR indicated a clear cutoff value at an eGFR
of 70 mL • min−1 • 1.73 m−2. Above this value, changes in eGFR
showed no association with the primary end point (Fig. 3;
Supplemental Fig. 1).
Estimated GFR as time-varying variable showed similar
associations with the primary outcome (HR 1.14, 95% CI
1.12–1.17; P < .001). In addition, eGFR assessed according
to KDOQI classification showed a gradual increase in event
rates with more severe KDOQI classes We found similar as-
sociations between eGFR/KDOQI classification and outcome
for each of the individual end points (Table 2).
In addition to baseline eGFR, changes over the 1st year
showed strong associations with clinical outcome. Every
10 mL • min−1 • 1.73 m−2 decrease in eGFR over the 1st year
was associated with a subsequent increase in the primary
end point (HR 1.10, 95% CI 1.04–1.17; P < .001). There
was a nonlinear association between the change in eGFR in
the 1st year of the study and subsequent outcome. Supple-
mental Fig. 2 shows the restricted cubic spline and associated
HR for the change in eGFR in the 1st year. It shows a clear
association between decrease in eGFR and worse clinical
outcome. With the use of no change in eGFR as the refer-
ence value, patients with 15 mL • min−1 • 1.73 m−2/year
decrease had the highest risk (HR 1.22, 95% CI 1.10–1.36),
followed by patients with 5 mL • min−1 • 1.73 m−2/year de-
crease (HR 1.10, 95% CI 1.06–1.14). Patients with
5 mL • min−1 • 1.73 m−2/year increase (HR 0.91, 95% CI 0.86–
0.96) or 15 mL • min−1 • 1.73 m−2/year increase (HR 0.84,
95% CI 0.75–0.95) had relatively better outcomes com-
pared with those with stable or deteriorating renal function
(Fig. 4).
Fig. 2. (A) Change in estimated glomerular filtration rate (eGFR) in patients with and without chronic obstructive pulmonary disease (COPD)
at baseline. (B) Change in eGFR in patients with and without loop diuretics at baseline. (C) Change in eGFR according to Kidney Disease
Outcomes Quality Initiatives (KDOQI) stages. *Too few serum creatinine values were available at this point (12 months) for the KDOQI
stage V group to allow accurate eGFR assessment for this group.
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Discussion
In patients with chronic HF included in the GISSI-HF
study, changes in renal function over time were of
modest magnitude. Overall, estimated GFR decreased by
2.57 mL • min−1 • 1.73 m−2/year, and one-fourth of patients had
progression of ≥1 CKD stage. Any decrease in eGFR over
time was associated with strongly increased event rates.
Changes in Renal Function and Progression of CKD
Recently, research in cardiorenal interaction has shifted from
assessment of baseline renal function to assessment of renal
function over time, although it had long been an important
research topic.3,10
Some analyses have given more insight into how renal func-
tion behaves during the longer time course of randomized trials.
In Val-HeFT (Valsartan Heart Failure), the mean change
in eGFR over the entire study period of 3 years was
2.9 mL • min−1 • 1.73 m−2 in the placebo group.4 In EMPHASIS-
HF (AComparison of Outcomes in Patients in NYHAFunctional
Class II Heart FailureWhen TreatedWith Eplerenone or Placebo
in Addition to Standard Heart Failure Medicines), annual de-
crease in eGFR was 0.066 mL • min−1 • 1.73 m−2 in the placebo
group,11 and in the I-PRESERVE (Irbesartan in Heart Failure
With Preserved Systolic Function) study eGFR decreased
5.0 mL • min−1 • 1.73 m−2 over 30 months in HF patients with
reduced ejection fraction.12 After hospitalization, eGFR seems
to deteriorate faster, as one study found that eGFR decreased
7 mL • min−1 • 1.73 m−2 in the 1st 18 months after discharge.13
In GISSI-HF, we found that estimated GFR decreased
3.7 mL • min−1 • 1.73 m−2 over 3 years. This was similar to the
change of the placebo group inVal-HeFT, but substantially higher
than the patients enrolled in EMPHASIS-HF.Although in GISSI-
HF a minority of patients had HF with preserved ejection fraction,
we did not find a significant interaction between the slope in
eGFR and LVEF, suggesting that changes in these groups were
similar. Importantly, the randomized treatment allocation in
Fig. 3. Hazard ratio for estimated glomerular filtration rate (eGFR) on continuous scale.
Table 2. Cox Proportional Hazard Analysis
Variable Combined End Point CV Death HF Hospitalization
Baseline
Multivariate
HR (95% CI) P Value
Multivariate
HR (95% CI) P Value
Multivariate
HR (95% CI) P Value
eGFR (per 10 mL • min−1 • 1.73 m−2 decrease) 1.10 (1.08–1.12) <.001 1.14 (1.11–1.17) <.001 1.10 (1.08–1.12) <.001
KDOQI stages <.001 <.001 <.001
Stage I (>90 mL • min−1 • 1.73 m−2) 1.00 (ref) 1.00 (ref) 1.00 (ref)
Stage II (60–90 mL • min−1 • 1.73 m−2) 1.16 (1.04–1.29) 1.00 (0.82–1.21) 1.19 (1.06–1.34)
Stage III (30–60 mL • min−1 • 1.73 m−2)) 1.55 (1.38–1.75) 1.54 (1.26–1.88) 1.60 (1.41–1.81)
Stage IV (15–30 mL • min−1 • 1.73 m−2) 2.35 (1.94–2.84) 2.59 (1.96–3.41) 2.40 (1.95–2.94)
Stage V (<15 mL • min−1 • 1.73 m−2) 1.47 (0.69–3.13) 2.86 (1.16–7.06) 1.50 (0.66–3.37)
Change in eGFR
Change in eGFR in 12 mo
(per 10 mL • min−1 • 1.73 m−2 decrease)
1.10 (1.04–1.17) <.001 1.08 (1.03–1.13) .001 1.12 (1.08–1.17) <.001
Change in eGFR in 12 mo <.001 .003 <.001
>15 mL • min−1 • 1.73 m−2 decrease 1.08 (0.93–1.26) 1.23 (1.01–1.51) 1.24 (1.10–1.40)
5–15 mL • min−1 • 1.73 m−2 decrease 1.10 (0.97–1.24) 1.12 (0.94–1.34) 1.21 (1.09–1.34)
−5 to +5 mL • min−1 • 1.73 m−2 (stable) 1.00 (ref) 1.00 (ref) 1.00 (ref)
5–15 mL • min−1 • 1.73 m−2 increase 0.81 (0.70–0.93) 0.82 (0.67–1.00) 0.89 (0.79–0.99)
>15 mL • min−1 • 1.73 m−2 increase 0.89 (0.75–1.06) 0.87 (0.67–1.13) 0.90 (0.78–1.05)
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GISSI-HF did not affect change in renal function, strength-
ening the overall applicability of our findings. In analogy to
de Silva et al, who investigated changes in CKD stages over a
6-month period and found that 19% deteriorated and 12% im-
proved ≥1 class during this period, we evaluated changes in
KDOQI stages across the study.14 In GISSI-HF, these numbers
were 25% for deterioration of ≥1 stage, and 14% for improve-
ment of ≥1 stage. In a retrospective analysis of SOLVD (Studies
of Left Ventricular Dysfunction) treatment, ~12% had a fast
deterioration of eGFR (>15 mL • min−1 • 1.73 m−2/year).15 The
figure in the 1st year of GISSI-HF was similar (15%), prob-
ably a reflection of patients with more severe HF in GISSI-HF
counterbalanced by less well treated patients in SOLVD. In that
particular analysis, most prominent predictors of this rapid decline
were female sex, higher baseline GFR, more severe HF, and
greater age. In comparison, we found that higher baseline GFR
and more severe HF (as indicated by loop diuretic use) were
associated with a steeper slope of eGFR change. The obser-
vation that higher baseline GFR was associated with steeper
decrease in eGFR is probably a reflection of regression to the
mean. Pulmonary disease was another factor associated with
a stronger decrease in eGFR, but this was not investigated in
SOLVD.15 Other studies on WRF have indicated similar as well
as different factors associated with change in GFR.3,14,16,17 Overall,
it seems that patients with more severe HF, greater age, and
more comorbidities, such as COPD, are at greater risk for a
steeper decline in GFR. This is in agreement with the present
findings, where patients with COPD had a slightly more rapid
decline in eGFR. One reason could be that patients with pul-
monary disease are more likely to have higher right-sided filling
pressures, which are now known to have a great effect on renal
function.Another reason could be that COPD and renal disease
share similar risk factors, such as smoking, atherosclerosis,
and chronic hypoxia. Putting these changes in renal function
in perspective, long-term observations in the general
(healthy) population have shown that eGFR declines
0.3–1.0 mL • min−1 • 1.73 m−2/year.1 This suggests that the mean
overall change in chronic HF patients in GISSI-HF was slightly,
but probably significantly, greater compared with the general
population and that a significant proportion of patients expe-
rience much larger yearly decreases in GFR compared with
what could have been expected from the general population.
Changes in Renal Function and Subsequent Outcome
Lower eGFR at any time has been shown to be associ-
ated with poor outcome, and, in general, similar associations
exist for deterioration of renal function, ie, WRF.3,18,19 However,
these changes in renal function have been evaluated during
a very short time period, mostly in-hospital or out-of-
hospital for up to 6 months. In a recent meta-analysis that
pooled all different WRF definitions and different patient popu-
lations, WRF was independently associated with poor clinical
outcome.3 This was apparent in both acute and chronic HF,
although it seems clear that a solitary increase in serum cre-
atinine in acute HF without further deterioration in the clinical
condition is probably clinically insignificant.20,21 In chronic
HF, the best data originate from retrospective analyses from
randomized clinical trials on renin-angiotensin-aldosterone
system (RAAS) inhibitors, and because of their inherent effect
on renal function, they are to some extent biased.4,11,19,22,23
However, these studies have shown that increases in serum
creatinine during initiation of RAAS inhibitors are not as-
sociated with poor outcome. Importantly, these trials had safety
protocols, where therapies should be down-titrated or dis-
continued when creatinine rose too high, which could have
influenced these associations. Furthermore, in our present anal-
ysis from GISSI-HF, 93% were on stable angiotensin-
converting enzyme inhibitor or angiotensin receptor blocker
therapy and more than one-third (39%) on spironolactone.
Only limited data exist on changes in renal function and
outcome in cohorts other than the mentioned randomized trial.
De Silva et al showed that 6-month mortality was ~5 times
higher in patients with concomitant severe baseline renal dys-
function and WRF compared with patients with normal
baseline renal function and no WRF.14 In a retrospective
Fig. 4. Kaplan-Meier curve of change in estimated glomerular filtration rate (eGFR) in the 1st year. Numbers on lines indicate change in
eGFR in mL • min−1 • 1.73 m−2 in the 1st year.
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analysis of patients recently discharged from hospital, WRF
directly after admission or from 6–12 months after admis-
sion was associated with significantly increased mortality
rates.13 In the present retrospective analysis of GISSI-HF, we
found that any deterioration in renal function during the 1st
year was associated with strongly increased event rates. Every
10 mL • min−1 • 1.73 m−2 decrease in eGFR was associated with
a 10% increase in the combined end point. This was further
supported by the finding that improvement in renal function
was associated with significantly better outcomes compared
with patients with relatively stable renal function, as well as
the finding that eGFR evaluated with the use of time-
varying analysis showed similar results. Overall, our findings
strongly suggest that any deterioration in renal function over
a moderately long period—whatever the cause—is associ-
ated with poorer clinical outcome, even if the decrease seems
clinically insignificant. This suggests that routine evalua-
tion of renal function in each HF patient is vital for the
assessment of clinical status and mortality/morbidity risk. It
also may help in selecting patients where deterioration of renal
function serves as a proxy of the progression of the disease
and who need more advanced HF therapy. This may also be
where the clinical relevance of serial assessment of renal func-
tion may come into play: it gives important information on
the (change in) severity of heart failure, an indication of the
subsequent prognosis, and, with the present data as informa-
tion on the “normal” change in eGFR, may give information
on more or less than expected changes in eGFR over time.
Whether or not this should result in more investigations and/
or change of therapy should be determined on a case-by-
case basis and cannot be deducted from the present analysis.
Study Limitations
This analysis of GISSI-HF is retrospective in nature, con-
sisting of data gathered in a trial population, and should
therefore be seen as hypothesis generating. The analysis can
only indicate associations and in no way can imply causal-
ity. Our results are also observational in nature. Decisions by
clinicians that could have affected renal function and outcome
were not taken into account, and this could have influenced
our analyses. Other significant limitations are estimation of
GFR rather than measurement, but the formula used in our
present analysis has been validated in chronic HF patients with
acceptable accuracy. We used the simplified MDRD formula,
because this was the formula used in the primary analysis
of GISSI-HF. Although the Chronic Kidney Disease–
Epidemiology Collaboration formula probably gives a better
estimate of GFR, differences in the changes in eGFR between
the 2 formulas are likely small. Although urinary albumin ex-
cretion was available in a subset of patients, it was available
at different time points for each patient and therefore not in-
cluded in this analysis. Major strengths of the present analysis
are the large population size and the noninterference of ran-
domized treatment with renal function, as well as the long
follow-up time.
Conclusion
Estimated GFR in chronic HF patients in GISSI-HF showed
a modest decrease over ≥3 years, although a significant pro-
portion of patients experienced much greater decreases in
eGFR. Baseline renal impairment, particularly (modest) de-
creases in eGFR over time, was associated with significantly
increased event rates. The results suggest that evaluation of
renal function should be part of the routine clinical work-
up of every chronic HF patient.
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